Navigation Links
MiddleBrook Pharmaceuticals Reports First Quarter 2008 Results
Date:5/13/2008

from the exercise of stock options and warrants, $0.3

million from the sale of fixed assets, and $0.3 million for working

capital changes and other items; offset by $6.7 million of operating

losses in the quarter.

-- The Balance Sheet at March 31, 2008 reflected $18.0 million of

unrestricted cash, cash equivalents and marketable securities, compared

to $2.0 million as of year-end 2007.

FINANCIAL GUIDANCE

MiddleBrook's financial guidance remains unchanged from prior forecasts. Total revenue for 2008 is expected to be approximately $10 million to $12 million, resulting from Keflex product sales and assuming no generic competition to Keflex 750 mg capsules occurs during the year. Total cash used in operating activities and capital expenditures in 2008 is estimated to be between $17 and $19 million. These forecasts also assume no financial impact from the Company's recently approved MOXATAG product, pending the outcome of its ongoing strategic process.

Assuming the Company's expectations for continued sales of its Keflex 750 mg product and anticipated level of R&D spending and other obligations, MiddleBrook believes that its current funds, together with expected Keflex product sales, will be sufficient to support its currently planned operations into 2009. These 2008 estimates are forward-looking statements that involve risks and uncertainties, and actual results could vary materially.

ABOUT MIDDLEBROOK PHARMACEUTICALS:

MiddleBrook Pharmaceuticals, Inc. (Nasdaq: MBRK) is a pharmaceutical company focused on the development and commercialization of anti-infective drug products that fulfill substantial unmet medical needs in the treatment of infectious disease. The C
'/>"/>

SOURCE MiddleBrook Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

Related medicine news :

1. MiddleBrook Pharmaceuticals Raises Up to $10 Million from Deerfield Management
2. MiddleBrook Pharmaceuticals Reports Third Quarter 2007 Results
3. MiddleBrook Pharmaceuticals to Raise $21 Million Through Private Placement of Common Equity
4. MiddleBrook Pharmaceuticals Engages Morgan Stanley in Its Strategic Process
5. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
6. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
7. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
8. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
9. Vista Partners Updates Coverage on Tapestry Pharmaceuticals
10. Transcept Pharmaceuticals, Inc. to Present at UBS 2007 Global Life Sciences Conference
11. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Tapestry Pharmaceuticals, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... HealthDay Reporter , MONDAY, Sept. 1, 2014 (HealthDay ... boost their heart health, cutting down on carbohydrates may work ... In a small clinical trial of obese adults, researchers found ... weight over a year than those who followed a low-fat ... and triglyceride levels, the research team reports in the Sept. ...
(Date:9/2/2014)... Moroccan Eco-Biologics’ new one-of-a-kind Vitality Hair Recovery ... the foundation of all natural Moroccan plant extracts to ... There is nothing similar to Vitality Hair Recovery cream ... is a commonly encountered problem for men and women ... been limited to existing medications offering mediocre results, considerable ...
(Date:9/2/2014)... September 02, 2014 Humility of Mary Health ... 18 at St. Elizabeth Health Center, 1044 Belmont Ave. , ... about more than 200 common health problems as well as ... and injury, and advice on when to seek medical attention. ... noon in the Youngstown Room; the evening session runs from ...
(Date:9/2/2014)... is pleased to announce that the following papers ... the ESC Congress 2014, taking place in Barcelona, ... Ultrathin strut biodegradable polymer sirolimus-eluting stent versus ... (BIOSCIENCE): a randomised, single-blind, non-inferiority trial, Windecker et ... strut thickness, surface polymer, and drug release have ...
(Date:9/2/2014)... NC (PRWEB) September 02, 2014 Researchers in ... woman who developed mesothelioma after being exposed to asbestos-contaminated work ... has all the details of the report in a new ... Doctors at the ESI Model Hospital say their patient was ... and breathlessness. Further investigation found that she had come in ...
Breaking Medicine News(10 mins):Health News:Low-Carb Beats Low-Fat for Weight Loss, Heart Health: Study 2Health News:Low-Carb Beats Low-Fat for Weight Loss, Heart Health: Study 3Health News:New All Natural, Organic Hair Recovery Products by Moroccan Eco-Biologics, Restore Lost Hair with No Side Effects 2Health News:HMHP Offers ‘Health at Home’ Workshop 2Health News:The Lancet: European Society of Cardiology Congress 2014 media alert 2Health News:New Report Illustrates That Even Brief Asbestos Exposure Can Trigger Mesothelioma, According to Surviving Mesothelioma 2
... , NEW YORK, Sept. 10 /PRNewswire-FirstCall/ - (OTCBB: GVBP.OB) ... develops novel therapeutic proteins that disrupt the advance of ... in the process of acquiring three promising new drug ... in royalty fees in the mid to long term. ...
... , , , ... to those who are here illegally," President Obama said in a carefully ... last night. The problem, notes the Federation for American Immigration Reform (FAIR), ... Health Care Act of 2009, clearly would benefit illegal aliens. , ...
... , , SAN FRANCISCO, ... professional association in U.S. history took a major step forward ... Nurses Association/National Nurses Organization in San Francisco voted unanimously to ... National Nurses United, unifying the 86,000-member CNA/NNOC with the ...
... (GSA) invites all journalists to attend its 62nd Annual ... the field of aging from November 18 to 22 ... An estimated 3,500 professionals are expected to attend the ... Atlanta Marriott Marquis . The theme for 2009 is "Creative ...
... The University of Miami School of Nursing and Health Studies ... Foundation in the amount of $30,000 to support six students ... program. "Family nurse practitioners have a promising future" said Nilda ... Studies. "The Dr. John T. Macdonald Foundation grant will help ...
... , , LAKE FOREST, Ill., ... leading global specialty pharmaceutical and medication delivery company, today announced that ... on Thursday, Sept. 17, 2009. The company,s senior leadership team and ... , A streaming audio webcast of the event, ...
Cached Medicine News:Health News:GENova to acquire three new drug target patents worth in excess of $1 billion in royalty fees 2Health News:GENova to acquire three new drug target patents worth in excess of $1 billion in royalty fees 3Health News:President Obama Misleads Public on Health Care for Illegal Aliens; Illegal Aliens Would Benefit Under H.R. 3200 2Health News:California Nurses/NNOC, Nation's Largest Nurses' Organization, Unanimously Endorses Joining RN Super Union 2Health News:An invitation to the nation's premier aging conference 2Health News:UM receives grant to support graduate students in the family nurse practitioner program 2Health News:Hospira to Host 2009 Investor Day 2
(Date:9/2/2014)... 2014  VentiRx Pharmaceuticals, Inc., a clinical ... and commercialization of novel Toll-like receptor 8 ... Food and Drug Administration (FDA) has granted ... motolimod (VTX-2337) when administered in combination with ... of women with ovarian cancer whose disease ...
(Date:9/2/2014)...   Intrexon Corporation (NYSE: XON ... it has entered into an Exclusive Channel Collaboration (ECC) ... (EURONEXT: SAN and NYSE: SNY ) to ... of its marketed Active Pharmaceutical Ingredients (APIs) through Sanofi,s ... This collaboration will leverage Intrexon,s proprietary technology suite plus ...
(Date:9/2/2014)... , Sept. 2, 2014   Veracyte, Inc. (Nasdaq: ... Anderson , president and chief executive officer, will present in ... Healthcare Unplugged Conference 2014 on Monday, September 8, 2014 at ... The live audio webcast and subsequent replay may ... Please connect to the website at least 15 minutes prior ...
Breaking Medicine Technology:VentiRx Pharmaceuticals Announces Fast Track Designation Granted for Motolimod (VTX-2337), a Novel Immunotherapy for Women with Ovarian Cancer 2VentiRx Pharmaceuticals Announces Fast Track Designation Granted for Motolimod (VTX-2337), a Novel Immunotherapy for Women with Ovarian Cancer 3Intrexon Announces Exclusive Channel Collaboration with Sanofi to Optimize Production for a Specific Family of Active Pharmaceutical Ingredients 2Intrexon Announces Exclusive Channel Collaboration with Sanofi to Optimize Production for a Specific Family of Active Pharmaceutical Ingredients 3Veracyte to Present at the Morgan Stanley Global Healthcare Unplugged Conference 2014 2
... YORK, Sept. 1, 2011 Reportlinker.com announces ... available in its catalogue: ... http://www.reportlinker.com/p0559262/Global-CRO-Market-Quantitative-Assessment.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_Discovery_and_Development This ... globally, by phase and market type, R&D ...
... This evening, Novo Nordisk awarded sponsorships totaling ... that educate people living with type 2 diabetes on ... risk of long-term diabetes related complications. The sponsorships are ... aims to promote enduring, sustainable change for people living ...
Cached Medicine Technology:Global CRO Market: Quantitative Assessment 2Global CRO Market: Quantitative Assessment 3Novo Nordisk Partners with Minneapolis Community Groups to Support Diabetes Education Programs 2
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: